Pharma

Your Article Summary

See Latest Articles

Genvec announces interim survival data in pivotal trial of tnferade in locally advanced pancreatic cancer
Corporate News Releases - The Healthcare Sales & Marketing Network, 11/20/08

GenVec, Inc. announced top-line results of an interim analysis from its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade (PACT) in patients with locally advanced pancreatic cancer. This interim analysis of overall survival, conducted after the 92nd death (one-third of total expected events), was designed to determine whether the study should continue and took place in the time frame originally estimated.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
Archives of Drug Information, 12/08/09

Autologous blood therapy for common cold—A randomized, double-blind, placebo-controlled trial
Complementary Therapies in Medicine, 12/08/09

Reduction of biofilm formation with trisodium citrate in haemodialysis catheters: a randomized controlled trial
Nephrology Dialysis Transplantation, 12/08/09

 See all of Drug Trials

Today in Financial Reports...keeping you current

Receive free subspecialty "5-minute updates" via email

Report: Acquisition Activity Down
HealthDataManagement, 12/08/09

Genzyme Provides Update on Cerezyme Supply and 2009 Financial Information
Genzyme, 12/07/09

Medtronic Board Approves Third Quarter Cash Dividend for Fiscal Year 2010
Medtronic, 12/04/09

 See all of Financial Reports